OTCMKTS:CYDY - CytoDyn Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.14 (-7.76%)

This chart shows the closing price for CYDY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CytoDyn Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYDY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYDY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for CytoDyn in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.67.

This chart shows the closing price for CYDY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in CytoDyn. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/17/2020HC WainwrightReiterated RatingHold
7/22/2020HC WainwrightReiterated RatingHold
7/14/2020HC WainwrightReiterated RatingHold
7/6/2020HC WainwrightDowngradeBuy ➝ Neutral
6/12/2020HC WainwrightReiterated RatingBuy$4.00
4/28/2020HC WainwrightReiterated RatingBuy$3.00 ➝ $4.00
4/13/2020HC WainwrightReiterated RatingBuy$3.00
4/3/2020HC WainwrightReiterated RatingBuy$1.50 ➝ $3.00
3/6/2020HC WainwrightReiterated RatingBuy$1.50
12/19/2019HC WainwrightReiterated RatingBuy$1.00 ➝ $1.50
9/16/2019HC WainwrightReiterated RatingBuy$1.50 ➝ $1.00
6/18/2019HC WainwrightReiterated RatingBuy
5/8/2019HC WainwrightSet Price TargetBuy$2.00
4/12/2019HC WainwrightSet Price TargetBuy$2.00
3/18/2019HC WainwrightReiterated RatingBuy$1.50
3/5/2019HC WainwrightSet Price TargetBuy$2.00
2/20/2019HC WainwrightReiterated RatingBuy$2.00
11/27/2018HC WainwrightInitiated CoverageBuy$2.00
11/13/2018HC WainwrightSet Price TargetBuy$2.00
11/6/2018HC WainwrightSet Price TargetBuy$2.00
10/10/2018HC WainwrightSet Price TargetBuy$2.00
9/14/2018HC WainwrightSet Price TargetBuy$2.00
9/6/2018HC WainwrightSet Price TargetBuy$2.00
8/16/2018HC WainwrightSet Price TargetBuy$2.00
7/31/2018HC WainwrightSet Price TargetBuy$2.00
7/13/2018HC WainwrightSet Price TargetBuy$2.00
5/25/2018HC WainwrightSet Price TargetBuy$2.00
3/9/2018HC WainwrightSet Price TargetBuy$2.00
2/13/2018HC WainwrightSet Price TargetBuy$2.00
12/8/2017HC WainwrightReiterated RatingBuy
11/29/2017HC WainwrightReiterated RatingBuy
8/10/2017HC WainwrightSet Price TargetBuy$2.00
12/14/2016HC WainwrightSet Price TargetBuy$2.00
10/6/2016Rodman & RenshawInitiated CoverageBuy$1.60
(Data available from 7/23/2016 forward)
CytoDyn logo
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Read More

Today's Range

Now: $1.67
Low: $1.65
High: $1.80

50 Day Range

MA: $1.80
Low: $1.37
High: $2.17

52 Week Range

Now: $1.67
Low: $1.35
High: $7.40


1,582,514 shs

Average Volume

3,679,507 shs

Market Capitalization

$1.04 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of CytoDyn?

The following sell-side analysts have issued research reports on CytoDyn in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for CYDY.

What is the current price target for CytoDyn?

0 Wall Street analysts have set twelve-month price targets for CytoDyn in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CytoDyn in the next year.
View the latest price targets for CYDY.

What is the current consensus analyst rating for CytoDyn?

CytoDyn currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CYDY, but not buy more shares or sell existing shares.
View the latest ratings for CYDY.

What other companies compete with CytoDyn?

How do I contact CytoDyn's investor relations team?

CytoDyn's physical mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company's listed phone number is 360-980-8524 and its investor relations email address is [email protected] The official website for CytoDyn is www.cytodyn.com.